Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 701-188-3 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
Terpineol multiconstituent and alpha-terpineol were found negative in several Ames tests.
Terpineol multiconstituent was also found negative in a recent GLP chromosome aberration test in human lymphocytes conducted according to OECD Guideline 473
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in bacteria
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 7 March 2006 - 9 May 2006
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- GLP study in compliance with OECD guideline 471 without any deviation.
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to other study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Deviations:
- no
- Principles of method if other than guideline:
- Not applicable
- GLP compliance:
- yes
- Type of assay:
- bacterial reverse mutation assay
- Target gene:
- Not applicable
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Details on mammalian cell type (if applicable):
- - Type and identity of media: bacterial broth medium
- Properly maintained: yes
- Periodically checked for karyotype stability: yes
- Periodically "cleansed" against high spontaneous background: yes - Species / strain / cell type:
- S. typhimurium TA 102
- Details on mammalian cell type (if applicable):
- - Type and identity of media: bacterial broth medium
- Properly maintained: yes
- Periodically checked for karyotype stability: yes
- Periodically "cleansed" against high spontaneous background: yes - Metabolic activation:
- with and without
- Metabolic activation system:
- Liver S9 fraction from Sprague Dawley rats treated with beta-naphtoflavone and phenobarbital
- Test concentrations with justification for top dose:
- Cytotoxicity test: 50, 150, 500, 1500 and 5000 µg/plate
Main test: 19, 56, 167, 500 and 1500 µg/plate - Vehicle / solvent:
- DMSO
- Justification for choice of solvent/vehicle: test substance not soluble in aqueous vehicles - Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- other: See table 1
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in agar (plate incorporation)
DURATION
- Preincubation period (before treatment): 13 h at 37°C
- Preincubation period (with test substance) in the second main experiment with S9: 30 min
- Exposure duration: 48 h at 37 °C
- Expression time (cells in growth medium): 48 h at 37 °C
SELECTION AGENT (mutation assays): minimum medium
NUMBER OF REPLICATIONS:
- cytotoxicity test: 1
- main test: 3
DETERMINATION OF CYTOTOXICITY
- Method: number of revertants
OTHER: 2 mL agar, 0.1 mL of test substance dilution, 0.1 mL of bacterial culture and 0.5 mL of S9 mix (when appropriate) were plated on solid minimum medium - Evaluation criteria:
- - statistically significant ratio (revertants with test substance / revertants with solvent) higher than 2 for TA 98, TA 100 and TA 102, and higher than 3 for TA 1535 and TA 1537
- increase in the number of revertants linked with the increase in test substance concentration
- reproducible results - Statistics:
- Dunett's test on revertants with test substance / revertants with solvent ratios.
- Key result
- Species / strain:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- at 5000 µg/plate for all strains and slightly to strong at 1500 µg/plate depending on the strains
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 102
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- strong at 1500 µg/plate
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Precipitation: no precipitation of the test substance was observed
RANGE-FINDING/SCREENING STUDIES: see table 4 for cytotoxicity results - Remarks on result:
- other: all strains/cell types tested
- Remarks:
- Migrated from field 'Test system'.
- Conclusions:
- Terpineol multiconstituent was found not to be mutagenic in TA 98, TA 100, TA 102, TA 1535 and TA 1537 with and without metabolic activation.
- Executive summary:
In a reverse gene mutation assay in bacteria, performed according to OECD Guideline 471 and in compliance with GLP, strains of S. typhimurium (TA 98, TA 100, TA 102, TA 1535 and TA 1537) were exposed to Terpineol multiconstituent at concentrations of 50, 150, 500, 1500 and 5000 µg/plate in both the absence and presence of S9 metabolic activation according to the direct plate incorporation method for a preliminary cytotoxicity test. In the main test, two experiments were performed at 19, 56, 167, 500 and 1500 µg/plate (up to cytotoxic concentrations) in both the absence and presence of S9. These experiments were performed according to the direct plate incorporation method except for the second experiment with S9 which was performed with a pre incubation period of 30 min with the test substance and S9 mix.
The positive controls induced the appropriate responses in the corresponding strains. Terpineol multiconstituent showed no biologically significant increases in revertant colony numbers over control count obtained with any of the tester strains at any concentrations in either presence or absence of S9 mix.
This study is classified as acceptable and satisfies the requirement for bacterial reverse gene mutation endpoint.
Therefore, Terpineol multiconstituent is not considered as mutagenic in this bacterial system according to CLP Regulation (EC) No 1272/2008.
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From April 04 to June 23, 2010
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- Well conducted and well described study in accordance with GLP and OECD guideline 473 without any deviation
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to other study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- Deviations:
- no
- Principles of method if other than guideline:
- Not applicable
- GLP compliance:
- yes
- Type of assay:
- in vitro mammalian chromosome aberration test
- Target gene:
- Not applicable
- Species / strain / cell type:
- lymphocytes: cultures prepared from the pooled blood of three male donors
- Additional strain / cell type characteristics:
- not applicable
- Metabolic activation:
- with and without
- Metabolic activation system:
- 2% S9 fraction of Aroclor 1254-induced male Sprague-Dawley rats
- Test concentrations with justification for top dose:
- Range-finder experiment: 5.598-1543 μg/mL (with and without S-9)
Main study:
- Experiment 1: Without S-9: 0, 350, 425 and 450 μg/mL; with S-9: 0, 300, 550 and 625 μg/mL
- Experiment 2: Without S-9: 0, 75, 200 and 225 μg/mL; with S-9: 0, 400, 550, 625 and 650 μg/mL - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: DMSO
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- DMSO
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- 4-nitroquinoline-N-oxide
- Remarks:
- without metabolic activation Migrated to IUCLID6: 2.5 and 5 µg/mL
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- DMSO
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- Remarks:
- with metabolic activation Migrated to IUCLID6: 10, 20 and 30 µg/mL
- Details on test system and experimental conditions:
- PREPARATION OF CULTURES: Whole blood cultures pooled from three healthy, non-smoking male volunteers were established in sterile disposable centrifuge tubes by placing 0.4 mL of pooled heparinised blood into 9.0 mL HEPES-buffered RPMI medium containing 20% (v/v) heat inactivated foetal calf serum and 50 µg/mL gentamycin, so that the final volume following addition of S9 mix or KCl and the test article in its chosen vehicle was 10 mL. The mitogen Phytohaemagglutinin (PHA, reagent grade) was included in the culture medium at a concentration of approximately 2% of culture to stimulate the lymphocytes to divide. Blood cultures were incubated at 37 ± 1 °C for approximately 48 hours and rocked continuously.
METHOD OF APPLICATION: In medium
DURATION
- Exposure duration: 3 or 20 hours, 37 ± 1 ºC
- Fixation time (start of exposure up to harvest of cells): 20 or 20.75 hours
SPINDLE INHIBITOR (cytogenetic assays): Colchicine, 1 µg/mL for 2 hours
STAIN (for cytogenetic assays): Giemsa (4% v/v)
NUMBER OF REPLICATIONS: Duplicates
NUMBER OF CELLS EVALUATED: At least 1000 cells/dose were counted in cytotoxicity test to determine the mitotic index; at least 200 metaphase cells/dose were analysed for chromosomal aberrations
DETERMINATION OF CYTOTOXICITY
- Method: Mitotic index
OTHER EXAMINATIONS:
- Cells with structural aberrations including or excluding gaps, polyploidy, hyperdiploidy or endoreduplication were recorded during the study. - Evaluation criteria:
- For valid data, the test article was considered to induce clastogenic events if:
1. A proportion of cells with structural aberrations at one or more concentrations that exceeded the normal range were observed in both replicate cultures
2. A statistically significant increase in the proportion of cells with structural aberrations (excluding gaps) was observed (p ≤ 0.05)
3. There was a concentration-related trend in the proportion of cells with structural aberrations (excluding gaps).
- Test article was considered as positive in this assay if all of the above criteria were met.
- Test article was considered as negative in this assay if none of the above criteria were met.
- Results which only partially satisfied the above criteria were dealt with on a case by case basis. - Statistics:
- - Statistical method used was Fisher's exact test.
- Proportions of aberrant cells in each replicate were also used to establish acceptable heterogeneity between replicates by means of a binomial dispersion test.
- Probability values of p ≤ 0.05 were accepted as significant. - Key result
- Species / strain:
- lymphocytes: human
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Effects of pH/osmolality: No marked changes in osmolality or pH were observed at the highest concentration tested in the range-finding cytotoxicity experiment (1543 µg/mL, equivalent to 10 mM), compared to the concurrent vehicle controls.
- Solubility/Precipitation: Miscible with anhydrous analytical grade dimethyl sulphoxide (DMSO) at a concentration of at least 174.6 mg/mL. Solubility limit in culture medium was approximately 873.1-1746 µg/mL as indicated by precipitation at the higher concentration which persisted for approximately 20 hours after test article addition.
RANGE-FINDING/SCREENING STUDIES:
- In the range-finding cytotoxicity study, precipitation was observed at or above 200 μg/mL and complete cytotoxicity was seen at or above 925.8 µg/mL tested with or without S-9.
- See table 2 for more data
COMPARISON WITH HISTORICAL CONTROL DATA: Proportion of cells with structural aberrations in negative control cultures fell within historical vehicle control (normal) ranges. - Remarks on result:
- other: all strains/cell types tested
- Remarks:
- Migrated from field 'Test system'.
- Conclusions:
- Terpineol multiconstituent is not considered as clastogenic in human lymphocytes according to CLP Regulation (EC) No 1272/2008.
- Executive summary:
In an in vitro chromosome aberration test performed according to OECD guideline 473 and in compliance with GLP, human primary lymphocyte cultures were exposed to terpineol multiconstituent in DMSO at concentration range of 5.598-1543 μg/mL, for 3 + 17 h (treatment + recovery) with metabolic activation (2% S-9 fraction of Aroclor 1254-induced male Sprague-Dawley rats), and for 3 + 17 h or 20 + 0 h (treatment + recovery) without metabolic activation for a preliminary cytotoxicity test. In the main test, two experiments were performed at concentrations up to 600 µg/mL without S-9 and up to 800 µg/mL with S-9 and the following concentrations were selected for analysis:
- Experiment 1: Without S-9 (treatment: 3 h): 0, 350, 425 and 450 μg/mL; with S-9 (treatment: 3 h): 0, 300, 550 and 625 μg/mL
- Experiment 2: Without S-9 (treatment: 20 h): 0, 75, 200 and 225 μg/mL; with S-9 (treatment: 3 h): 0, 400, 550, 625 and 650 μg/mL
Proportion of cells with structural aberrations in negative control cultures fell within historical vehicle control ranges. Positive controls (4-nitroquinoline-N-oxide at 2.5 and 5 µg/mL without S-9 and cyclophosphamide at 10, 20 and 30 µg/mL with S-9) induced the appropriate response. Treatment of cells with terpineol multiconstituent in the presence or absence of S-9 in both experiments resulted in frequencies of cells with structural or numerical aberrations that were generally similar to those observed in concurrent vehicle controls for all concentrations analysed. Numbers of aberrant cells (excluding gaps) in treated cultures fell within the normal range with the exception of one culture at the highest concentration analysed with S-9 in experiment 1 (625.0 µg/mL). However, the aberration frequency (excluding gaps) in the replicate culture at 625.0 µg/mL in experiment 1 and in all other cultures analysed in experiments 1 and 2 fell within the normal range.
Therefore, terpineol multiconstituent is not considered as clastogenic in human lymphocytes according to CLP Regulation (EC) No 1272 /2008.
- Endpoint:
- in vitro gene mutation study in bacteria
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- supporting study
- Justification for type of information:
- Alpha-terpineol is one of the main constituents of multiconstituent substance TERPINEOL MULTICONSTITUENT. Therefore, data on alpha-terpineol can be used for extrapolation to TERPINEOL MULTICONSTITUENT.
- Reason / purpose for cross-reference:
- read-across source
- Key result
- Species / strain:
- S. typhimurium TA 102
- Metabolic activation:
- with and without
- Genotoxicity:
- positive
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- an alteration of the background lawn at 2000 µg/plate with S9 and a decrease in revertant number at 1250 µg/plate without S9
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium, other: TA 97a, TA98 and TA100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- an alteration of the background lawn at 2000 and 2500 µg/plate for TA 100 and TA 98 with S9
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- no data
- Remarks on result:
- other: all strains/cell types tested
- Remarks:
- Migrated from field 'Test system'.
- Conclusions:
- alpha-Terpineol was found mutagenic with and without S9 in TA 102 strain but was non mutagenic with and without S9 in TA97a, TA98 and TA100 strains.
- Executive summary:
In a reverse gene mutation assay in bacteria performed in non GLP conditions but similarly to OECD guideline 471, TA97a, TA98, TA100 and TA102 strains of S. typhimurium were exposed to alpha-terpineol at concentrations between 0 and 2500 µg/plate in the presence and absence of mammalian metabolic activation system (lyophilized rat liver S9 fraction induced by Aroclor 1254).
alpha-Terpineol was tested for cytotoxicity at different dose concentrations. The toxicity appeared at 2500 µg/plate with S9 and at 2000 µg/plate without S9 for TA100 strain. The positive controls induced the appropriate responses in the corresponding strains.
alpha-Terpineol caused dose-related increase in the number of histidine revertants with TA102 tester strain with and without S9. There was no evidence of concentration related positive response for induced mutant colonies over background in the other strains with and without S9.
- Endpoint:
- in vitro gene mutation study in bacteria
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- supporting study
- Justification for type of information:
- Alpha-terpineol is one of the main constituents of multiconstituent substance TERPINEOL MULTICONSTITUENT. Therefore, data on alpha-terpineol can be used for extrapolation to TERPINEOL MULTICONSTITUENT.
- Reason / purpose for cross-reference:
- read-across source
- Key result
- Species / strain:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- not specified
- Vehicle controls validity:
- not applicable
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- not applicable
- Key result
- Species / strain:
- S. typhimurium TA 1538
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- not specified
- Vehicle controls validity:
- not applicable
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- not applicable
- Remarks on result:
- other: all strains/cell types tested
- Remarks:
- Migrated from field 'Test system'.
- Conclusions:
- alpha-Terpineol is not considered as mutagenic in the bacterial system according to CLP Regulation (EC) No 1272/2008.
- Executive summary:
In a reverse gene mutation assay in bacteria performed similarly to OECD Guideline 471, strains of S. typhimurium (TA 1535, TA 1537, TA 1538, TA 100 and TA 98) were exposed to alpha-terpineol up to 10000 µg or nL/plate in both the absence and presence of metabolic activation (S9 fraction of Aroclor 1254-induced adult male Sprague-Dawley rat liver) according to the direct plate incorporation method.
Alpha terpineol showed no substantial increases in revertant colony numbers obtained with any of the tester strains up to the highest concentration tested in either presence or absence of S9 mix.
Therefore, alpha-terpineol is not considered as mutagenic in this bacterial system according to CLP Regulation (EC) No 1272 /2008.
- Endpoint:
- in vitro gene mutation study in bacteria
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- supporting study
- Justification for type of information:
- Alpha-terpineol is one of the main constituents of multiconstituent substance TERPINEOL MULTICONSTITUENT. Therefore, data on alpha-terpineol can be used for extrapolation to TERPINEOL MULTICONSTITUENT.
- Reason / purpose for cross-reference:
- read-across source
- Key result
- Species / strain:
- S. typhimurium, other: TA98, TA100, TA1535, TA1537 and TA1538
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- not specified
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- no data
- Remarks on result:
- other: all strains/cell types tested
- Remarks:
- Migrated from field 'Test system'.
- Conclusions:
- alpha-Terpineol was not mutagenic in the Ames test in both plate incorporation and preincubation methods with and without metabolic activation.
- Executive summary:
In a reverse gene mutation assay in bacteria conducted similarly to OECD guideline 471, TA98, TA100, TA1535, TA1537 and TA1538 strains of S. typhimurium were exposed to alpha-terpineol at concentrations between 1µg and 1000 µg/plate in the presence and absence of mammalian metabolic activation system liver S9 homogenate, from male Sprague-Dawley rats and Syriyan golden hamsters injected with Aroclor 1254 at 500 mg/kg body weight.
alpha-Terpineol was tested for mutagenicity at different dose concentrations with both direct plate incorporation and preincubation methodology. alpha-Terpineol caused no dose-related response in the number of histidine auxotroph revertants. The positive controls induced the appropriate responses in the corresponding strains.
- Endpoint:
- in vitro gene mutation study in mammalian cells
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- supporting study
- Justification for type of information:
- Alpha-terpineol is one of the main constituents of multiconstituent substance TERPINEOL MULTICONSTITUENT. Therefore, data on alpha-terpineol can be used for extrapolation to TERPINEOL MULTICONSTITUENT.
- Reason / purpose for cross-reference:
- read-across source
- Key result
- Species / strain:
- mouse lymphoma L5178Y cells
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- The doses of chemical selected for testing were with in the range yielding approximately 0-90 % cytotoxicity
- Vehicle controls validity:
- not specified
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- no data
- Remarks on result:
- other: strain/cell type:
- Remarks:
- Migrated from field 'Test system'.
- Conclusions:
- Test results confirmed previous results showing negative response both with and without metabolic activation.
- Executive summary:
In a mammalian cell gene mutation assay conducted similarly to OECD guideline 476, mouse lymphoma L5178Y cells cultured in vitro were exposed to alpha-terpineol at concentrations between 0.14 µg/mL and 0.65 µg/mL in the presence and absence of metabolic activation with liver S9 prepared from Aroclor 1254-induced male Sprangue-Dawley rats.
alpha-Terpineol was tested for cytotoxic concentration up to an upper limit of 10000 µg/plate. In both nonactivated and S9-activated conditions, response was negative at a dose 0.14-0.65 µg/mL The positive controls ethylmethylsulfonate (without metabolic activation) and 3-methylcholanthrene (with metabolic activation) induced the appropriate response.
Referenceopen allclose all
Table 2: results of the first main experiment
Strain |
Compound |
Dose level (µg/plate) |
S9 mix |
Mean revertant colony counts |
SD |
Ratio treated/solvent |
Individual revertant colony counts |
TA 98 |
DMSO
2 nitrofluorene
DMSO
2-aminoanthracene |
19 56 167 500 1500 1
19 56 167 500 1500 2 |
- - - - - - -
+ + + + + + + |
19 18 17 17 17 5 319
22 23 25 25 24 20 2653 |
4 2 3 3 4 5 46
5 6 7 4 7 4 150 |
0.9 0.9 0.9 0.9 0.3 *
1.0 1.1 1.1 1.1 0.9
|
23, 16, 19 19, 20, 16 14, 18, 20 19, 19, 14 13, 21, 17 3, 2, 11 320, 364, 273
27, 22, 18 16, 27, 25 29, 17, 29 30, 22, 23 18, 23, 32 24, 19, 17 2520, 2624, 2816 |
TA 100 |
DMSO
Sodium azide
DMSO
2-aminoant-racene |
19 56 167 500 1500 1.5
19 56 167 500 1500 2 |
- - - - - - -
+ + + + + + + |
74 81 79 90 85 60 155
94 137 140 105 120 102 3397 |
6 6 16 12 12 17 15
12 3 3 3 14 9 411 |
1.1 1.0 1.2 1.1 0.8
1.5 * 1.5 * 1.1 1.3 * 1.1
|
71, 81, 70 74, 86, 82 65, 76, 97 79, 102, 89 95, 71, 88 79, 46, 55 141, 154, 171
102, 80, 101 135, 140, 136 140, 137, 142 106, 107, 102 105, 125, 131 107, 108, 92 3152, 3872, 3168 |
TA 102 |
DMSO
Mitomycine C
DMSO
Benzo(a)pyrene |
19 56 167 500 1500 0.125
19 56 167 500 1500 4 |
- - - - - - -
+ + + + + + + |
192 193 225 125 73 0 1339
214 232 266 158 153 5 436 |
8 30 8 50 29 0 368
16 35 23 9 32 3 26 |
1.0 1.2 0.7 * 0.4 * 0.0 *
1.1 1.2 0.7 * 0.7 * 0.0 *
|
188, 186, 201 228, 172, 180 232, 216, 228 156, 68, 152 63, 51, 106 1060, 1200, 1756
208, 232, 201 212, 272, 212 288, 268, 242 158, 167, 149 176, 167, 116 3, 4, 8 464, 414, 429 |
TA 1535 |
DMSO
Azide sodium
DMSO
2-aminoanthracene |
19 56 167 500 1500 1.5
19 56 167 500 1500 2 |
- - - - - - -
+ + + + + + + |
13 13 14 16 10 2 685
11 6 8 9 9 4 111 |
4 1 1 7 4 2 24
2 1 2 1 1 1 35 |
1.1 1.1 1.3 0.8 0.1 *
0.5 * 0.7 * 0.8 0.8 0.3 * |
14, 8, 16 13, 13, 14 14,14, 15 9, 22, 17 5, 12, 12 0, 4, 1 658, 704, 694
11, 12, 9 6, 6, 5 7, 10, 6 8, 9, 9 8, 8, 10 3, 4, 4 149, 81, 103 |
TA 1537 |
DMSO
9-aminoacridine
DMSO
2-aminoanthracene |
19 56 167 500 1500 40
19 56 167 500 1500 2 |
- - - - - - -
+ + + + + + + |
10 6 7 10 6 7 957
7 6 4 9 8 3 192 |
6 4 2 1 2 2 93
3 1 1 2 3 3 28 |
0.5 0.7 1.0 0.5 0.6
0.8 0.6 1.3 1.1 0.4 *
|
17, 5, 9 3, 4, 10 5, 7, 9 10, 10, 11 7, 4, 6 9, 6, 5 1002, 1018, 850
10, 5, 7 5, 6, 7 4, 4, 5 7, 11, 10 6, 7, 12 6, 2, 1 161, 202, 214 |
* statistically significant (p<0.05)
Table 3: results of the second main experiment
Strain |
Compound |
Dose level (µg/plate) |
S9 mix |
Mean revertant colony counts |
SD |
Ratio treated/solvent |
Individual revertant colony counts |
TA 98 |
DMSO
nitro-2-fluorene
DMSO
2-aminoanthracene |
19 56 167 500 1500 1.5
19 56 167 500 1500 1 |
- - - - - - -
+ + + + + + + |
22 22 15 22 16 6 360
21 28 28 27 13 2 1229 |
5 4 2 2 3 2 60
9 6 2 9 6 4 85 |
1.0 0.7 * 1.0 0.7 0.3 *
1.3 1.3 1.3 0.6 0.1 *
|
23, 16, 26 24, 24, 17 16, 15, 13 23, 20, 24 19, 13, 15 8, 5, 6 316, 428, 336
30, 13, 20 33, 22, 28 29, 29, 26 35, 27, 18 20, 8, 11 0, 0, 7 1140, 1308, 1240 |
TA 100 |
DMSO
Sodium azide
DMSO
2-aminoanthracene |
19 56 167 500 1500 1.5
19 56 167 500 1500 1 |
- - - - - - -
+ + + + + + + |
90 80 67 90 78 54 201
94 92 97 129 82 36 808 |
8 8 7 12 18 1 20
3 8 19 23 16 49 78 |
0.9 0.7 * 1.0 0.9 0.6 *
1.0 1.0 1.4 0.9 0.4 *
|
92, 82, 97 72, 87, 80 72, 59, 70 91, 78, 101 59, 80, 95 54, 54, 55 223, 185, 195
92, 93, 97 98, 83, 95 114, 100, 77 102, 138, 146 64, 95, 86 0, 16, 92 812, 884, 728 |
TA 102 |
DMSO
Mitomycine C
DMSO
Benzo(a)pyrene |
19 56 167 500 1500 0.125
19 56 167 500 1500 2 |
- - - - - - -
+ + + + + + + |
180 205 159 154 105 4 1131
107 137 110 98 93 0 214 |
47 33 15 10 8 4 110
10 4 19 14 19 0 18 |
1.1 0.9 0.9 0.6 * 0.0 *
1.3 * 1.0 0.9 0.9 0.0 *
|
228, 178, 134 228, 168, 220 175, 147, 154 150, 147, 165 95, 110, 109 0, 8, 4 1192, 1004, 1196
100, 118, 103 142, 136, 134 93, 131, 106 113, 85, 95 76, 88, 114 0, 0, 0 218, 229, 194 |
TA 1535 |
DMSO
Azide sodium
DMSO
2-aminoanthracene |
19 56 167 500 1500 1.5
19 56 167 500 1500 1 |
- - - - - - -
+ + + + + + + |
13 16 18 13 11 6 647
9 11 10 5 3 0 218 |
2 2 2 1 3 2 50
3 2 3 2 2 0 12 |
1.2 1.3 1.0 0.8 0.4 *
1.2 1.1 0.6 0.3 * 0.0 * |
15, 12, 13 15, 15, 18 19, 18, 16 12, 13, 13 11, 8, 14 7, 7, 3 670, 590, 682
6, 10, 12 10, 11, 13 13, 9, 8 7, 5, 4 2, 5, 1 0, 0, 0 205, 229, 219 |
TA 1537 |
DMSO
9-aminoacridine
DMSO
2-aminoanthracene |
19 56 167 500 1500 40
19 56 167 500 1500 1 |
- - - - - - -
+ + + + + + + |
10 7 10 6 7 3 336
6 9 7 7 9 0 45 |
1 4 3 4 4 3 118
2 0 1 2 14 0 6 |
0.7 1.0 0.6 0.6 0.3 *
1.4 1.2 1.1 1.5 0.0 * |
11, 11, 9 12, 4, 5 13, 10, 8 11, 4, 4 3, 10, 7 0, 3, 6 468, 242, 298
5, 8, 6 9, 9, 9 7, 8, 7 5, 7, 8 26, 2, 0 0, 0, 0 38, 49, 48 |
* statistically significant (p<0.05)
Table 2: Range-finder experiment: mitotic index determinations
Treatment |
Mitotic index (%) |
||||||||
(µg/mL) |
3+17 hours, -S-9 |
3+17 hours, +S-9 |
20+0 hours, -S-9 |
||||||
|
A |
B |
MIH* |
A |
B |
MIH* |
A |
B |
MIH* |
Vehicle |
5.7 |
7.4 |
- |
7.0 |
5.1 |
- |
5.9 |
6.7 |
- |
5.598 |
6.2 |
NT |
5 |
6.7 |
NT |
0 |
6.0 |
NT |
5 |
9.330 |
5.6 |
NT |
15 |
5.7 |
NT |
6 |
6.3 |
NT |
0 |
15.55 |
7.7 |
NT |
0 |
5.1 |
NT |
16 |
5.4 |
NT |
14 |
25.92 |
4.5 |
NT |
31 |
6.2 |
NT |
0 |
5.3 |
NT |
16 |
43.19 |
6.0 |
NT |
8 |
7.8 |
NT |
0 |
6.4 |
NT |
0 |
71.99 |
6.2 |
NT |
5 |
6.2 |
NT |
0 |
6.0 |
NT |
5 |
120.0 |
6.8 |
NT |
0 |
7.1 |
NT |
0 |
4.9 |
NT |
22 |
200.0 |
6.4 |
NT |
2P |
4.0 |
NT |
34P |
4.5 |
NT |
29P |
333.3 |
6.1 |
NT |
7P |
4.8 |
NT |
21P |
2.2 |
NT |
65P |
555.5 |
0.0 |
NT |
100P |
4.0 |
NT |
34P |
0.0 |
NT |
100P |
925.8 |
T |
NT |
100P |
T |
NT |
100P |
T |
NT |
100P |
1543 |
T |
NT |
100P |
T |
NT |
100P |
T |
NT |
100P |
NT = Not tested; P = Precipitation observed at treatment; T = Toxic
*Mitotic inhibition (%) = [1 - (mean MIT/mean MIC)] x 100%
(where T = treatment and C = negative control)
Table 3: Results summary
Treatment |
Concentration (mg/mL) |
Cytotoxicity (%) |
% Cells with Chromosome Aberrations (Excluding Gaps) |
Historical (%)# |
Statistical significance |
Experiment 1 |
|||||
3+17.75 hour -S-9 |
Vehiclea |
- |
0.50 |
0-3 |
- |
|
350.0 |
0 |
0.50 |
|
NC |
|
425.0 |
29 |
1.00 |
|
NC |
|
450.0 |
50 |
0.50 |
|
NC |
|
*NQO, 2.50 |
ND |
8.00 |
|
p ≤ 0.001 |
3+17.75 hour +S-9 |
Vehiclea |
- |
0.50 |
0-3 |
- |
|
300.0 |
0 |
1.00 |
|
NC |
|
550.0 |
35 |
3.00 |
|
NC |
|
625.0 |
50 |
5.00 |
|
NC |
|
*CPA, 10.00 |
ND |
25.83 |
|
p ≤ 0.001 |
Experiment 2 |
|||||
20+0 hour -S-9 |
Vehiclea |
- |
1.00 |
0-3 |
- |
|
75.00 |
18 |
0.00 |
|
NC |
|
200.0 |
34 |
1.50 |
|
NC |
|
225.0 |
53 |
1.00 |
|
NC |
|
*NQO, 5.00 |
ND |
29.37 |
|
p ≤ 0.001 |
3+17 hour +S-9 |
Vehiclea |
- |
0.50 |
0-3 |
- |
|
400.0 |
7 |
0.50 |
|
NC |
|
550.0 |
34 |
1.50 |
|
NC |
|
625.0 |
39 |
2.50 |
|
NC |
|
650.0 |
50 |
1.00 |
|
NC |
|
*CPA, 20.00 |
ND |
42.11 |
|
p ≤ 0.001 |
a Vehicle control was DMSO
* Positive control
#95th percentile of the observed range
NC = Not calculated
ND = Not determined
Table: 2 Toxicity of alpha terpineol compound to S.typhimurium TA 100 strain
Dose (µg /plate) |
-S9 |
+S9 |
3000 |
- |
0 / 3 |
2750 |
- |
- |
2500 |
- |
180 ± 11 |
2000 |
68/0/0 |
184 ± 8 |
1500 |
126 ± 35 |
- |
1250 |
145 ± 6 |
- |
1000 |
164 ± 5 |
- |
900 |
- |
- |
800 |
- |
- |
700 |
- |
- |
600 |
- |
- |
500 |
- |
- |
400 |
- |
- |
300 |
- |
- |
200 |
- |
- |
0 |
167 ± 6 |
166 ± 2 |
PC |
913 ± 65 |
464 ± 35 |
Table 3: Mutagenicity testing of alpha terpineol in the Salmonella / microsome assay [TA100, TA98, TA97a and TA102 tester strains]
Dose (µg /plate) |
TA 100 |
TA 98 |
TA 97a |
TA 102 |
||||
|
-S9 |
+S9 |
-S9 |
+S9 |
-S9 |
+S9 |
-S9 |
+S9 |
2500 |
- |
141 ± 62* |
- |
4 /0/0 |
- |
- |
- |
- |
2000 |
53 ± 14* |
146 ± 2 |
- |
68 ± 13 |
- |
272 ± 34 |
- |
833 ± 57* |
1500 |
165 ± 16 |
212 ± 28 |
43 ± 5 |
60 ± 10 |
225 |
248 ± 12 |
- |
1573 ± 191 |
1250 |
158 ± 19 |
188 ± 23 |
42 ± 2 |
58 ± 2 |
224 ± 11 |
246 ± 6 |
862 ± 187 |
1727 ± 108 |
1000 |
176 ± 6 |
208 ± 33 |
40 ± 8 |
54 ± 10 |
191 ± 8 |
254 ± 21 |
1004 ± 488 |
1429 ± 46 |
750 |
177 ± 14 |
196 ± 1 |
36 ± 4 |
69 ± 10 |
216 ± 16 |
246 ± 12 |
1418 ± 176 |
1177 ± 42 |
500 |
177 ± 12 |
161 ± 24 |
28 ± 7 |
53 ± 10 |
195 ± 13 |
241 ± 16 |
1312 ± 89 |
1116 ± 74 |
250 |
186 ± 9 |
- |
30 ± 6 |
- |
182 ± 12 |
- |
812 ± 166 |
790 ± 47 |
100 |
- |
- |
- |
- |
- |
- |
924 ± 151 |
- |
50 |
- |
- |
- |
- |
- |
- |
737 ± 32 |
- |
25 |
- |
- |
- |
- |
- |
- |
611 ± 65 |
- |
0 |
176 ± 14 |
197 ± 7 |
40 ± 7 |
70 ± 6 |
158 ± 2 |
214 ± 18 |
731 ± 36 |
771 ± 37 |
PC |
898 ± 51 |
742 ± 13 |
192 ± 31 |
312 ± 33 |
1098 ± 80 |
870 ± 140 |
4875 ± 1031 |
2024 ± 182 |
Dose O- Negative control: 100 µl ethanol PA; PC-Positive control
(-) Dose not tested.
(*) Toxicity apparent as an alternation of the background lawn
(/+) mutant counts of individual plates
None
None
None
Genetic toxicity in vivo
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Terpineol multiconstituent and alpha-terpineol were found negative in several Ames tests with and without metabolic activation. A GLP study on terpineol multiconstituent conducted according to OECD guideline 471 was identified as key study.
Terpineol multiconstituent was also found negative in a recent GLP chromosome aberration test in human lymphocytes conducted according to OECD guideline 473, identified as key study.
alpha-Terpineol was negative in a gene mutation test conducted similarly to OECD guideline 476 using mouse lymphoma tk+/- L5178Y cells with and without metabolic activation.
Justification for classification or non-classification
Terpineol multiconstituent was negative in an Ames test and in a chromosome aberration test. alpha-Terpineol showed similar mutagenicity properties as terpineol multiconstituent in several Ames tests and was found negative in an in vitro gene mutation test in mammalian cells. Therefore, terpineol multiconstituent is considered as non mutagenic and is not classified as mutagenic according to CLP Regulation (EC) No 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.